Premium
Infrared Responsive Choline Phosphate Lipids for Synergistic Cancer Therapy
Author(s) -
Jiang Sangni,
Wang Wenliang,
Dong Lihua,
Yan Xinxin,
Li Shengran,
Mei Weikang,
Xie Xintao,
Zhang Yuanhua,
Liu Sanrong,
Yu Xifei
Publication year - 2021
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.202101626
Subject(s) - nanocarriers , cancer cell , in vivo , chemistry , cancer research , cytotoxicity , in vitro , liposome , cancer , biocompatibility , cancer therapy , biophysics , pharmacology , drug delivery , medicine , biochemistry , biology , microbiology and biotechnology , organic chemistry
Abstract Choline phosphate lipids have been designed and developed as new‐generation zwitterionic nanocarriers with excellent biocompatibility and bioorthogonality to provide a more programmable performance for cancer therapy. However, there is a lack of spatiotemporal and reversible control for drug release at target tumor cells, which can lead to severe adverse effects to normal tissue and discounted treatment outcome. Here, light‐inducible Lip‐cRGDfk/ICG/Dox liposomes were developed for synergistic cancer therapy. ICG can effectively convert light energy into selective heating in a local environment upon laser irradiation, thus inducing thermal ablation of tumor cells, and further reversibly trigger the spatiotemporal release of anticancer drugs (Dox) at tumor cells due to the conformation transformation of CP lipids to synergistically kill tumor cells. That Lip‐cRGDfk/ICG/Dox exhibited a significant improvement for breast cancer therapy in vitro and in vivo is also demonstrated, thus it can serve as an efficient platform to noninvasively and spatiotemporally control the activation of cytotoxicity at tumor cells for precision cancer therapy.